Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PC.

Mol Cancer Ther. 2012 May;11(5):1214-5. doi: 10.1158/1535-7163.MCT-12-0210. Epub 2012 Mar 29. No abstract available.

2.

Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.

Stevenson M, Mostertz W, Acharya CR, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A.

Clin Cancer Res. 2012 Mar 15;18(6):1818. doi: 10.1158/1078-0432.CCR-12-0337. Epub 2012 Feb 21. No abstract available.

3.

Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2012 Feb 1;307(5):453. doi: 10.1001/jama.2012.2. Epub 2012 Jan 6. No abstract available.

PMID:
22228686
4.

A pathway-based approach to identify molecular biomarkers in cancer.

Stevenson M, Potti A.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S620-4. doi: 10.1245/s10434-011-1855-4. Epub 2011 Nov 3.

PMID:
22048630
5.

Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569. doi: 10.1073/pnas.1115170108. Epub 2011 Oct 3. No abstract available.

6.

Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.

Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR.

N Engl J Med. 2011 Mar 24;364(12):1176. doi: 10.1056/NEJMc1101915. Epub 2011 Mar 2.

7.

Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2011 Feb;12(2):116. doi: 10.1016/S1470-2045(11)70011-0. No abstract available.

PMID:
21277543
8.

Retraction: Genomic signatures to guide the use of chemotherapeutics.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR.

Nat Med. 2011 Jan;17(1):135. doi: 10.1038/nm0111-135. No abstract available.

PMID:
21217686
9.

Refocusing the war on cancer: the critical role of personalized treatment.

Potti A, Schilsky RL, Nevins JR.

Sci Transl Med. 2010 Apr 21;2(28):28cm13. doi: 10.1126/scitranslmed.3000643.

PMID:
20410527
10.

The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design.

Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS.

BMC Cancer. 2010 Apr 21;10:155. doi: 10.1186/1471-2407-10-155.

11.

A pathway-based classification of human breast cancer.

Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6994-9. doi: 10.1073/pnas.0912708107. Epub 2010 Mar 24.

12.

Age- and sex-specific genomic profiles in non-small cell lung cancer.

Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, Lamlertthon W, Barry W, Crawford J, Nevins J, Potti A.

JAMA. 2010 Feb 10;303(6):535-43. doi: 10.1001/jama.2010.80.

PMID:
20145230
13.

Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.

Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A.

Clin Cancer Res. 2009 Dec 15;15(24):7553-61. doi: 10.1158/1078-0432.CCR-09-1939. Retraction in: Stevenson M, Mostertz W, Acharya CR, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Clin Cancer Res. 2012 Mar 15;18(6):1818.

14.

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR.

Clin Cancer Res. 2009 Nov 15;15(22):6947-55. doi: 10.1158/1078-0432.CCR-09-1132. Epub 2009 Oct 27.

15.

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B.

J Clin Oncol. 2009 Nov 20;27(33):5580-6. doi: 10.1200/JCO.2009.22.2547. Epub 2009 Oct 26.

PMID:
19858393
16.

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Laubach JP, Fu P, Jiang X, Salter KH, Potti A, Arcasoy MO.

Exp Hematol. 2009 Dec;37(12):1411-22. doi: 10.1016/j.exphem.2009.09.009. Epub 2009 Oct 6.

17.

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.

Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16387-92. doi: 10.1073/pnas.0901250106. Epub 2009 Sep 4.

18.

Utilization of genomic signatures to identify phenotype-specific drugs.

Mori S, Chang JT, Andrechek ER, Potti A, Nevins JR.

PLoS One. 2009 Aug 28;4(8):e6772. doi: 10.1371/journal.pone.0006772.

19.

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM.

Breast Cancer Res. 2009;11(4):R55. doi: 10.1186/bcr2344. Epub 2009 Jul 28. Erratum in: Breast Cancer Res. 2011;13(4):406.

20.

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A.

J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Epub 2009 Jul 27. Erratum in: J Clin Oncol. 2012 Apr 20;30(12):1398.

21.

Translating genomics into clinical practice: applications in lung cancer.

Jolly Graham A, Potti A.

Curr Oncol Rep. 2009 Jul;11(4):263-8. Review.

PMID:
19508830
22.

Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008).

Aebersold R, Auffray C, Baney E, Barillot E, Brazma A, Brett C, Brunak S, Butte A, Califano A, Celis J, Cufer T, Ferrell J, Galas D, Gallahan D, Gatenby R, Goldbeter A, Hace N, Henney A, Hood L, Iyengar R, Jackson V, Kallioniemi O, Klingmüller U, Kolar P, Kolch W, Kyriakopoulou C, Laplace F, Lehrach H, Marcus F, Matrisian L, Nolan G, Pelkmans L, Potti A, Sander C, Seljak M, Singer D, Sorger P, Stunnenberg H, Superti-Furga G, Uhlen M, Vidal M, Weinstein J, Wigle D, Williams M, Wolkenhauer O, Zhivotovsky B, Zinovyev A, Zupan B.

Mol Oncol. 2009 Feb;3(1):9-17. doi: 10.1016/j.molonc.2008.11.003. Epub 2008 Dec 9.

23.

A genomic strategy to elucidate modules of oncogenic pathway signaling networks.

Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR.

Mol Cell. 2009 Apr 10;34(1):104-14. doi: 10.1016/j.molcel.2009.02.030.

24.

Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. doi: 10.1073/pnas.0900827106. Epub 2009 Mar 11. Erratum in: Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14705.

25.

Genomic and molecular profiling predicts response to temozolomide in melanoma.

Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS.

Clin Cancer Res. 2009 Jan 15;15(2):502-10. doi: 10.1158/1078-0432.CCR-08-1916. Erratum in: Clin Cancer Res. 2009 May 1;15(9):3240.

26.

A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7. doi: 10.1073/pnas.0806674105. Epub 2008 Dec 2. Erratum in: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6878. Retraction in: Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569.

27.

Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, Potti A, Bild A, Nevins JR.

Cancer Res. 2008 Oct 15;68(20):8525-34. doi: 10.1158/0008-5472.CAN-08-1329.

28.

A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG.

Mol Cancer Ther. 2008 Oct;7(10):3141-9. doi: 10.1158/1535-7163.MCT-08-0642. Erratum in: Mol Cancer Ther. 2012 May;11(5):1214-5.

29.

Toward the individualization of lung cancer therapy.

Anguiano A, Nevins JR, Potti A.

Cancer. 2008 Oct 1;113(7 Suppl):1760-7. doi: 10.1002/cncr.23644.

30.

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL.

J Clin Oncol. 2008 Jul 10;26(20):3324-30. doi: 10.1200/JCO.2007.14.2471. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
18612148
31.

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.

Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A.

JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. Retraction in: Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. JAMA. 2012 Feb 1;307(5):453.

PMID:
18387932
32.

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A.

PLoS One. 2008 Apr 2;3(4):e1908. doi: 10.1371/journal.pone.0001908. Retraction in: PLoS One. 2011;6(9). doi: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4.

33.

Utilization of genomic signatures to direct use of primary chemotherapy.

Potti A, Nevins JR.

Curr Opin Genet Dev. 2008 Feb;18(1):62-7. doi: 10.1016/j.gde.2008.01.018. Epub 2008 Mar 12. Review.

PMID:
18339540
34.

Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.

Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A.

PLoS One. 2008 Jan 2;3(1):e1373. doi: 10.1371/journal.pone.0001373.

35.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
36.

Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer.

Anguiano A, Potti A.

Expert Rev Mol Diagn. 2007 Nov;7(6):837-44. Review.

PMID:
18020912
37.

Genomic strategies for personalized cancer therapy.

Garman KS, Nevins JR, Potti A.

Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32. Review.

PMID:
17911165
38.

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A.

J Clin Oncol. 2007 Oct 1;25(28):4350-7. Erratum in: J Clin Oncol. 2010 Jun 1;28(16):2805. Retraction in: J Clin Oncol. 2010 Dec 10;28(35):5229.

PMID:
17906199
39.

Mining gene expression profiles: expression signatures as cancer phenotypes.

Nevins JR, Potti A.

Nat Rev Genet. 2007 Aug;8(8):601-9. Epub 2007 Jul 3. Review.

PMID:
17607306
40.

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.

J Clin Oncol. 2007 Feb 10;25(5):517-25. Retraction in: J Clin Oncol. 2012 Feb 20;30(6):678.

PMID:
17290060
41.

Genomic signatures in non-small-cell lung cancer: targeting the targeted therapies.

Dressman HK, Bild A, Garst J, Harpole D Jr, Potti A.

Curr Oncol Rep. 2006 Jul;8(4):252-7. Review.

PMID:
17254524
42.
43.

Genomic signatures to guide the use of chemotherapeutics.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR.

Nat Med. 2006 Nov;12(11):1294-300. Epub 2006 Oct 22. Erratum in: Nat Med. 2007 Nov;13(11):1388. Nat Med. 2008 Aug;14(8):889. Retraction in: Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Nat Med. 2011 Jan;17(1):135.

PMID:
17057710
44.

Linking oncogenic pathways with therapeutic opportunities.

Bild AH, Potti A, Nevins JR.

Nat Rev Cancer. 2006 Sep;6(9):735-41. Epub 2006 Aug 17. Review.

PMID:
16915294
45.

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR.

N Engl J Med. 2006 Aug 10;355(6):570-80. Erratum in: N Engl J Med. 2007 Jan 11;356(2):201-2. Retraction in: Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. N Engl J Med. 2011 Mar 24;364(12):1176.

46.

Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future.

Potti A, Ganti AK.

Expert Opin Biol Ther. 2006 Jul;6(7):709-16. Review.

PMID:
16805710
47.

Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease.

Namboodiri AM, Moffett JR, Arun P, Mathew R, Namboodiri S, Potti A, Hershfield J, Kirmani B, Jacobowitz DM, Madhavarao CN.

Adv Exp Med Biol. 2006;576:145-63; discussion 361-3. Review. No abstract available.

PMID:
16802710
48.
49.

Ineffectiveness of the measurement of 'routine' vital signs for adult inpatients with community-acquired pneumonia.

Mariani P, Saeed MU, Potti A, Hebert B, Sholes K, Lewis MJ, Hanley JF.

Int J Nurs Pract. 2006 Apr;12(2):105-9.

PMID:
16529596
50.

Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis.

Lewis DA, Nyska A, Potti A, Hoke HA, Klemp KF, Ward SM, Peddada SD, Wu J, Ortel TL.

Thromb Res. 2006;118(6):747-53. Epub 2006 Jan 6.

PMID:
16405975

Supplemental Content

Support Center